Introduction
Imatinib mesylate (imatinib, Gleevec, STI571), a selective BCR-ABL tyrosine-kinase inhibitor, has shown significant activity against Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) and Ph-positive acute lymphocytic leukemia (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . The estimated 2-year incidence of resistance to imatinib was 80% in blastic phase, 40% to 50% in accelerated phase, and 10% in chronic phase post interferon alpha failure. Mechanisms of resistance to imatinib include overexpression of Bcr-Abl, BCR-ABL oncogene amplification, mutations within the ABL activation site, increased levels of plasma 1 acid glycoprotein, and cytogenetic clonal evolution (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Several strategies to overcome imatinib resistance are being investigated (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . One approach is to increase the dose of imatinib. The rationale for this is the overexpression of Bcr-Abl and amplification of BCR-ABL as mechanisms of resistance; the pre-clinical studies and clinical experience showing a dose-response effect; the experience in CML accelerated phase in which a dose of 600 mg of imatinib was independently associated with significantly better time to transformation, and survival compared to 400 mg; and anecdotal experience of responsiveness to higher doses of imatinib in patients whose CML had become resistant to lower doses. Herein, we summarize our experience in patients with Ph-positive CML in chronic phase post interferon failure who received an escalated dose of 800 mg or 600 mg orally daily after demonstrating a poor response or relapse at the standard dose.
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Patients and Methods
We analyzed the course of 261 patients with Ph-positive CML in chronic phase post-interferon failure treated on two Novartis-sponsored trials: the pivotal study (Study 110; 149 patients treated at our institution), and the expanded access study (Study 113; 112 patients). Patients signed an informed consent according to institutional guidelines. The entry criteria, pre-treatment and followup studies, and dose modification guidelines have been previously detailed (3, 5, 9) . The protocol design allowed for dose escalation of imatinib from 400 mg daily to 400 mg twice daily, or to 600 mg daily if the dose had been reduced to 300 mg daily, under the following circumstances: 1) failure to achieve a complete hematologic response (CHR) after 3 months of therapy (hematologic resistance);
2) failure to achieve a major cytogenetic response (Ph-positive cells <35%) after 12 months of therapy (cytogenetic resistance); 3) hematologic relapse; or 4) cytogenetic relapse defined as an increase of Ph-positive cells by 30% documented on two consecutive occasions. Response criteria were previously described (5, 9) . A complete hematologic 
Results and Discussion
Among the 261 patients treated, 54 patients fulfilled the above resistancerelapse criteria, and agreed to be treated at the higher dose. Their characteristics are shown in Table 1 . Their median age was 58 years (range 24 to 77 years). The median time from diagnosis to therapy was 32 months (range 5 to 131 months) and the median duration of imatinib therapy was 13 months (range, 3 to 27 months). Forty-seven patients received imatinib 800mg daily, and 7 received imatinib 600mg daily. Response by the different categories of response to standard-dose imatinib are detailed in Table 2 . Three additional patients have improved from 100% Ph-positive to 45%, 45%, and 55% Ph-positive, respectively. Among 7 patients with a minor cytogenetic response, 1 achieved a complete and 4 a partial cytogenetic response.
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Six patients were treated for hematologic resistance: 3 achieved CHR, and 1 of them had a partial cytogenetic response.
Thus, among 20 patients treated for active CML disease not responding to standard-dose imatinib, 13 (65%) achieved a hematologic response (9 CHR, 4 PHR), but only 1 (5%) has achieved a major cytogenetic response. Among 34 patients treated for cytogenetic resistance or relapse, 13 patients (38%) have achieved a major cytogenetic response: 6 complete, and 7 partial. Six patients have shown minor responses or improvements and 4 continue on therapy. The details of cytogenetic responses are shown in Table 3 .
Twenty-tw o patients had reductions in the dose of imatinib from 800 to 600 mg or 400 mg due to severe pancytopenia (N=13), or other toxicities (N=9; fatigue, gastrointestinal, skin rash, bone aches, edema, and dizziness). The median actual dose delivered at 3 (n=47) and 6 (n=41) months was 800 mg.
After a median follow-up of 8+ months (range, 1 to 26+ months), 38 patients remained on imatinib in chronic phase while 16 patients discontinued therapy because of hematologic (n=8) or cytogenetic (n=2) resistance, transformation to accelerated (N=3) or blastic phase (N=2), or sudden unrelated death (N=1).
Eleven patients have died, 10 following discontinuation of imatinib, and 1 while on imatinib (infection-2, cardiac failure-2, blastic phase-4, bleeding-1, other-2).
Overcoming resistance to imatinib therapy in CML can be achieved through several hypothetical approaches. These include increasing the dose of For personal use only. on September 14, 2017. by guest www.bloodjournal.org From imatinib, using inhibitors of downstream pathways to Bcr-Abl (e.g. farnesyl transferase inhibitors), combining imatinib with established (interferon alpha, cytarabine) or investigational (homoharringtonine, decitabine) therapies, or circumventing specific mechanisms of resistance (e.g., MDR blocking agents).
The present analysis demonstrates that higher doses of imatinib may reinduce hematologic response or improve the cytogenetic responses in some patients whose CML had shown hematologic or cytogenetic resistance to standard-dose imatinib. Although we cannot rule out the possibility that responses would occur with continuation of standard-dose imatinib, many of the responders had already lost their response. In addition, the larger experience with imatinib suggests that hematologic responses typically occur within 3 months and major CG responses occur infrequently after 12 months of therapy (5) . All patients with hematologic failure had received imatinib for at least 3 months and those with cytogenetic failure for at least 12 months. Some patients in this report have only achieved a minor cytogenetic response with short follow-up, and it is possible that some of these responses may become major responses with longer therapy.
Several mechanisms of resistance have been described after imatinib therapy, including clonal evolution, point mutations, and overexpression and amplification of Bcr/Abl. The mechanism of resistance to standard dose was not evaluated in this study. This could be an important factor to determine which patients may respond to increasing doses of imatinib and should be addressed in future studies.
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